Related references
Note: Only part of the references are listed.HER2 aberrations in cancer: Implications for therapy
Min Yan et al.
CANCER TREATMENT REVIEWS (2014)
Expression of Topoisomerase II Alpha, ki67, and p53 in Primary Non-Muscle-Invasive Urothelial Bladder Carcinoma
Soumaya Ben Abdelkrim et al.
JOURNAL OF IMMUNOASSAY & IMMUNOCHEMISTRY (2014)
Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study
Michael Rink et al.
EUROPEAN UROLOGY (2012)
HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder
Hans Olsson et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2012)
Assessment of Human Epidermal Growth Factor Receptor 2 Status in Urothelial Carcinoma of the Upper Urinary Tract: A Study Using Dual-color In Situ Hybridization and Immunohistochemistry
Marie Vershasselt-Crinquette et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2012)
Different HER2 Protein Expression Profiles Aid in the Histologic Differential Diagnosis Between Urothelial Carcinoma In Situ (CIS) and Non-CIS Conditions (Dysplasia and Reactive Atypia) of the Urinary Bladder Mucosa
Sven Gunia et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours
Achim Fleischmann et al.
EUROPEAN UROLOGY (2011)
European Guidelines for the Diagnosis and Management of Upper Urinary Tract Urothelial Cell Carcinomas: 2011 Update
Morgan Roupret et al.
EUROPEAN UROLOGY (2011)
HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization
Christina B. Ching et al.
MODERN PATHOLOGY (2011)
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
M. Lae et al.
ANNALS OF ONCOLOGY (2010)
Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder
Christian Bolenz et al.
BJU INTERNATIONAL (2010)
HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
Dorte Lisbet Nielsen et al.
CANCER TREATMENT REVIEWS (2009)
Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17
Sara Simonetti et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2009)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
HER-2 and topoisomerase II as predictors of response to chemotherapy
Kathleen I. Pritchard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Yuh-Shyan Tsai et al.
UROLOGIA INTERNATIONALIS (2007)
Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase II alpha expression?
Cristina Corzo et al.
TUMOR BIOLOGY (2007)
Frequency and clinicopathologic correlates of Erb131, Erb132, and Erb133 immunoreactivity in urothelial tumors of upper urinary tract
YS Tsai et al.
UROLOGY (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: Systematic analysis applying tissue microarray technique
C Langner et al.
UROLOGY (2005)
Human DNA topoisomerase-IIα expression as a prognostic factor for transitional cell carcinoma of the urinary bladder
R Koren et al.
BJU INTERNATIONAL (2003)
Predictive value of topoisomerase IIα immunostaining in urothelial bladder carcinoma
L Nakopoulou et al.
JOURNAL OF CLINICAL PATHOLOGY (2001)
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
RC Bast et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
